Okogen Doses First Patient in Phase 1/2 Treyegen Trial
The Phase 1/2 EMERALD trial is evaluating Treyegen for acute infectious conjunctivitis.
Related stories
PAMT Corp. Q3 loss widens on higher fuel costs
PAMT Corp. reported a wider Q3 loss, with higher fuel costs cited. The body also says revenue rose 8%, but is truncated.
M impact | EQUITY | Nov 02, 2026, 09:33 PM UTC
India Signs Rs.53,866 Crore Contracts for Eight Navy Corvettes
India signed defence contracts worth Rs.53,866 crore to build eight next-generation corvettes for the Indian Navy.
M impact | EQUITY | Nov 02, 2026, 09:33 PM UTC
Red Robin Completes Sale of 108 Restaurants for About $89.4 Million
Red Robin completed the sale of 108 restaurants for approximately $89.4 million.
M impact | EQUITY | Nov 02, 2026, 09:33 PM UTC
People Incorporated Reports 6% Q3 Decline in Session-Based Revenue
People Incorporated said session-based revenue declined 6% in Q3, reflecting accelerated impact from AI-oriented search and content discovery experiences.
M impact | EQUITY | Nov 02, 2026, 09:33 PM UTC
BRC Q3 Revenue Beats on Wholesale Strength
M impact | EQUITY | Nov 02, 2026, 09:33 PM UTC
EverQuote Sees Q4 2026 Revenue of $213M-$223M
M impact | EQUITY | Nov 02, 2026, 09:32 PM UTC